Journal: Addictive Behaviors Reports

Article Title: Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study

doi: 10.1016/j.abrep.2025.100654

Figure Lengend Snippet: Differential Effects of CBD on Pain Modulation Among Participants Receiving Methadone and Buprenorphine. Bar graphs showing responses to CBD at doses of 400 mg, 800 mg, and 1200 mg measured at 120 and 240 min post-administration. Data presented as mean ± standard error with individual data points. Treatment groups are indicated by 'm' (methadone, n = 4) and 'b' (buprenorphine, n = 3). Significant between-group differences are indicated by * (p < 0.05) and *** (p < 0.001). (A) Heat Pain Threshold: Percent change from baseline showing opposing responses between treatment groups at 400 mg. (B) Heat Pain Tolerance: Divergent responses, with significant between-group differences observed at 120 min post-800 mg and near-significant differences at 240 min post-400 mg dose. (C) Top-Down Pain Modulation − Conditioned Pain Modulation (CPM): Positive values indicate enhanced pain modulation, primarily observed in the buprenorphine group at 400 mg dose. (D) Bottom-Up Pain Facilitation − Temporal Summation of Pain (TSP): Higher values indicate increased pain facilitation. Significant between-group difference at 1200 mg (240 min). Y-axis represents percent change from baseline for all measures. For CPM (C), values represent the percent change from baseline of the within-session CPM effect (calculated as % inhibition).

Article Snippet: Participants completed three 8-hour test sessions with ascending doses of oral CBD (Epidiolex®): 400 mg, 800 mg, and 1200 mg. Epidiolex is a solution containing purified, plant-derived CBD at concentration of 100 mg/mL, obtained from Jazz Pharmaceuticals ( ).

Techniques: Inhibition

Journal: Addictive Behaviors Reports

Article Title: Exploring the effects of cannabidiol on pain sensitivity using quantitative sensory testing among individuals receiving methadone or buprenorphine for opioid use disorder: an open-label, proof-of-concept study

doi: 10.1016/j.abrep.2025.100654

Figure Lengend Snippet: Effects of Different CBD Doses on Craving, Safety, and Cognitive Function in Individuals Receiving Methadone and Buprenorphine. Bar graphs showing responses to CBD across three doses (400 mg, 800 mg, 1200 mg) with individual data points and mean ± standard error. Significant between-group differences indicated by * (p < 0.05). (A) Adverse Events: SAFTEE severity across doses for both medication groups showing no significant differences in treatment-emergent adverse events. (B) Cue-Induced Craving: Percent change in Heroin Craving Questionnaire (HCQ) scores post-cue from baseline. Effects varied by MOUD type and dose, with the 400 mg dose associated with the largest percentage reduction for the methadone group, and the 1200 mg dose associated with the largest percentage reduction for the buprenorphine group. (C) Cognitive Performance: Throughput scores on the Continuous Performance Test showing an increase in average Throughput scores across doses for both MOUD groups. (D) Verbal Memory: HVLT delayed recall scores demonstrating minimal between-group differences and stability across CBD doses, suggesting preserved memory function.

Article Snippet: Participants completed three 8-hour test sessions with ascending doses of oral CBD (Epidiolex®): 400 mg, 800 mg, and 1200 mg. Epidiolex is a solution containing purified, plant-derived CBD at concentration of 100 mg/mL, obtained from Jazz Pharmaceuticals ( ).

Techniques: